National Institutes of Health: Pheochromocytoma trials

The registry lists 18 Pheochromocytoma studies with National Institutes of Health as lead sponsor. 7 are open to participants now and 5 have results posted.

Phase 1 4Phase 2 11No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersRecruitingNCT06479811Phase 1
• Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand TherapyRecruitingNCT06427798Phase 1/2
• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 1
• Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaRecruitingNCT03206060Phase 2
• Diagnosis of PheochromocytomaRecruitingNCT00004847Phase 1
• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruitingNCT00001238
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
• Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompletedNCT01967576Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or ParagangliomaTerminatedNCT01340794Phase 2Results posted
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2Results posted
• Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Natural History Study of Children and Adults With Medullary Thyroid CancerActive, not recruitingNCT01660984
• 131MIBG to Treat Malignant PheochromocytomaCompletedNCT00028106Phase 2
• Diagnosis and Treatment of PheochromocytomaCompletedNCT00001229
• Blood Sampling for Neurochemical and Genetic TestingCompletedNCT00001147